Zami Aberman
2013
In 2013, Zami Aberman earned a total compensation of $1.7M as Chief Executive Officer at Pluristem Therapeutics, a 11% increase compared to previous year.
Compensation breakdown
| Bonus | $75,000 |
|---|---|
| Salary | $488,910 |
| Stock Awards | $1,078,000 |
| Other | $21,042 |
| Total | $1,662,952 |
Aberman received $1.1M in stock awards, accounting for 65% of the total pay in 2013.
Aberman also received $75K in bonus, $488.9K in salary and $21K in other compensation.
Rankings
In 2013, Zami Aberman's compensation ranked 4,551st out of 12,286 executives tracked by ExecPay. In other words, Aberman earned more than 63.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,551 out of 12,286 | 63rd |
Division Manufacturing | 1,556 out of 4,612 | 66th |
Major group Chemicals And Allied Products | 447 out of 1,462 | 69th |
Industry group Drugs | 310 out of 1,156 | 73rd |
Industry Biological Products, Except Diagnostic Substances | 47 out of 196 | 76th |
Source: SEC filing on March 31, 2014.
Aberman's colleagues
We found one more compensation record of an executive who worked with Zami Aberman at Pluristem Therapeutics in 2013.
2013
Yaky Yanay
Pluristem Therapeutics
Chief Financial Officer
News
Pluristem Therapeutics CEO Yaky Yanay's 2022 pay falls 86% to $1.3M
February 27, 2023
Pluristem Therapeutics Chairman Zami Aberman's 2020 pay falls 54% to $501K
April 8, 2021
Pluristem Therapeutics Chairman Zami Aberman's 2019 pay jumps 85% to $1.1M
May 20, 2020
Pluristem Therapeutics CEO Zami Aberman's 2018 pay falls 83% to $593K
April 25, 2019